Setijono et al. [92] showed that miR-218 expression was downregulated in breast cancer cells, and the gene targeted by miR-218 was LMNB1. Saleh et al. [93] reported for the first time that the LMNB1 expression level was relatively high in both normal and malignant breast tissues, with an average positive expression rate of 93% and 88%, respectively; however, in malignant breast cancer cells exposed to neoadjuvant chemotherapy, LMNB1 expression was sharply reduced, with an average positive expression rate of 55%. Here, LMNB1 is linked to breast cancer.